



Gimv

Good company for companies

Press release

Antwerp / 1 March 2011 / 7:30 CET

Gimv announces an agreement to sell portfolio company Plexxikon to Daiichi Sankyo

Successful exit leads to positive impact of EUR 1.32 per share

Gimv today announced that Daiichi Sankyo (www.daiichisankyo.com) has signed a binding agreement for the acquisition of portfolio company Plexxikon (USA). Under the terms of the agreement Daiichi Sankyo has agreed a purchase price for Plexxikon of USD 805 million upfront. Subsequent milestone payments associated with the approval of the companies lead compound (PLX4032) could total an additional USD 130 million USD. Closing of the transaction is subject to antitrust clearance under the Hart-Scott Rodino Antitrust Improvements Act.

Plexxikon (www.plexxikon.com) is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's lead compound, PLX4032, recently met its co-primary endpoints in a Phase 3 clinical trial in patients with previously untreated metastatic melanoma with the BRAF mutation.

In addition to PLX4032, Plexxikon has a pipeline of additional products in development and pre-development, including multiple agents to treat cancer. Plexxikon's proprietary Scaffold-Based Drug Discovery™ platform integrates multiple state-of-the-art technologies, including structural screening as a key component that provides a significant competitive advantage over other drug discovery approaches. The company was founded in 2001 and is headquartered in Berkeley, California. To date Plexxikon raised approximately USD 67 million in three venture rounds, led by a group of highly experienced and well-regarded biotechnology investors.

Gimv is a shareholder of Plexxikon since the series B financing round in 2002, together with Alta Partners, ATV, Walden International, Pappas Ventures and CW Ventures. Gimv is the sole European investor within this group of international investors.

The sale has a positive impact of EUR 30.5 million (EUR 1.32 per share) on Gimv's last published equity value at 31 December 2010. Over the entire investment period, the shareholding's return is significantly above Gimv's historic average. No further financial details on this transaction will be disclosed.

Plexxikon is Gimv's sixth venture capital exit over the past twelve months, after having sold Movetis to Shire, Liquavista to Samsung, CoreOptics to Cisco, L&C to Nuance and Coware to Synopsis.

Annex: 1) press release Plexxikon



Gimv

Good company for companies

Press release

For further information, please contact:

Mr Frank De Leenheer – Investor Relations & Corporate Communications Manager
T +32 3 290 22 18 – frank.deleenheer@gimv.com

Dr. Jim Van heusden – Partner Venture Capital
T +32 3 290 21 57 – jim.vanheusden@gimv.com

Gimv is a European investment company with 30 years' experience in private equity and venture capital. The company is listed on the NYSE Euronext Brussels and manages around 1.8 billion EUR (including third parties' funds).

Gimv invests in buyouts and provides growth financing to established companies. For this Gimv has four local teams in Belgium, the Netherlands, France and Germany. Through the Gimv-XL fund growth capital is invested in larger companies in Flanders. In high-tech sectors Gimv invests venture capital through its specialized teams in Life Sciences, Technology and Cleantech.

In the Benelux Gimv also focuses on infrastructure projects with its DG Infra+ and DG Infra Yield funds. Additionally, Gimv is active in Central and Eastern Europe through funds and joint ventures.

More information on Gimv can be found at www.gimv.com



Plexxikon

DAIICHI SANKYO TO ACQUIRE PLEXXIKON

--Deal Accelerates Expansion of Oncology Franchise--

Berkeley, CA—February 28, 2011—Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company. The purchase price for Plexxikon is \$805 million up-front. Near-term milestone payments associated with the approval of PLX4032 could total an additional \$130 million. Closure of the transaction is subject to clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act and customary closing conditions.

Plexxikon's lead program is PLX4032, an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Interim data from a Phase 3 controlled study of PLX4032 in previously untreated metastatic melanoma patients with the BRAF mutation met both co-primary endpoints. Patients treated with PLX4032 had improved overall survival (OS) and improved progression-free survival (PFS) compared to patients treated with dacarbazine, the current standard of care. The company and its co-development partner, Roche, plan to file for market approval in the U.S. and Europe this year, along with a filing for the companion diagnostic also being co-developed by the partners. Earlier this year, Plexxikon announced an agreement to co-promote PLX4032 in the U.S. with Roche's U.S. commercial oncology unit, Genentech. Following the acquisition, Daiichi Sankyo will retain the U.S. co-promotion rights for PLX4032.

“With the acquisition of Plexxikon, we see an opportunity to accelerate the building of our oncology franchise, particularly with the opportunity to co-promote PLX4032 as a very exciting personalized medicine,” said Joji Nakayama, chief executive officer of Daiichi Sankyo, Co., Ltd. “Moreover, we have been impressed by the productivity and quality of Plexxikon's pipeline, and discovery and early development capabilities. We intend to provide a high degree of independence to the Plexxikon group to support their continuing success.”

“Since 2001, Plexxikon's novel drug discovery and development approach, along with our unique business model, has led to the development of a portfolio of well-differentiated product candidates spanning multiple therapeutic indications,” said K. Peter Hirth, Ph.D., chief executive officer of Plexxikon. “We are particularly proud of the advancement of PLX4032 as a truly personalized medicine combined with a companion diagnostic, and our near-term opportunity for commercialization. We are pleased that Daiichi Sankyo recognizes the value not only of the commercial opportunity of PLX4032, but also of Plexxikon's robust pipeline and discovery

engine. Together, now with Daiichi Sankyo, we hope to leverage Plexxikon's accelerated discovery and development capabilities in a unique but supportive structure."

In addition to PLX4032, Plexxikon has a pipeline of additional products in development and pre-development, including multiple agents to treat cancer. PLX3397 is an oral, selective kinase inhibitor co-targeting Fms, Kit and Flt3-ITD, and is currently in the late stages of a Phase 1 dose escalation trial. The company plans to initiate several Phase 2 trials with PLX3397 in specific cancers this year, including Hodgkin lymphoma, AML, glioblastoma and metastatic breast cancer. Additionally, the company has just initiated a Phase 1 study for PLX5622, an oral agent directed to the treatment of rheumatoid arthritis.

Daiichi Sankyo Group, based in Tokyo, is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

About Plexxikon

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company is developing a portfolio of clinical and preclinical stage compounds to address significant unmet medical needs in cardio-renal disease, CNS disorders, autoimmune and neuro-inflammatory diseases, and oncology. Plexxikon's proprietary Scaffold-Based Drug Discovery™ platform integrates multiple state-of-the-art technologies, including structural screening as a key component that provides a significant competitive advantage over other drug discovery approaches. For more information, please visit www.plexxikon.com.

Contacts:

Kathleen Sereda Glaub

President

Plexxikon Inc.

+1 (510) 647-4009

kglaub@plexxikon.com

For Plexxikon

Susan Kinhead

+1 (415) 751-3611

susan@kinheadcomm.com

or

Jennifer Cook Williams

+1 (360) 668-3701

jennifer@cwcomm.org